The Europe animal healthcare market is estimated to be valued at USD 15,270.3 Mn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period (2024-2031). Rising awareness about animal health among pet owners as well as farm owners is driving the market growth. Furthermore, advancements in animal healthcare products and services along with growing veterinary infrastructure is expected to fuel the market growth in the coming years.
Market Dynamics:
Rising pet ownership continues to be a key driver for the Europe animal healthcare market. According data published by Health for Animals, a global animal health association, it was stated that over 65 million pets are owned across countries in Europe representing a significant consumer base. Growing humanization of pets has led owners to spend more on healthcare and nutrition of their pets. This is positively impacting the sales of vaccines, parasiticides and other pet care products in the region. Another major factor propelling the market growth is increasing meat consumption which has intensified animal farming activities. Farm owners are increasingly focusing on animal health and productivity to cater to the rising demand for meat and dairy. This has augmented the demand for animal healthcare products like feed additives, parasiticides and vaccines especially for cattle and pigs. Leading players are also investing in development of advanced veterinary drugs and solutions to better address
Increased Veterinary Healthcare Expenditure
Veterinary healthcare expenditure in Europe has seen steady growth over the past decade. According to the data by European Commission, veterinary healthcare spending in Europe reached US$ 11.7 billion in 2020 and is projected to exceed $15 billion by 2027. This increase can be attributed to rising pet ownership, growing awareness about pet health, and higher disposable incomes which have allowed pet owners to spend more on veterinary care and services. Higher spending on vet care means increased demand for animal healthcare products like vaccines, parasiticides and other pharmaceuticals which act as a key driver for this market.
Growing Focus on Zoonotic Diseases
There is growing awareness in Europe about zoonotic diseases which can be transmitted from animals to humans. Diseases like rabies, avian influenza, anthrax have raised concerns among public health officials and regulatory bodies. This has led governments to implement stringent regulations for monitoring and control of zoonotic diseases. Animal healthcare product manufacturers are developing new vaccines and therapeutics to help curb the spread of these diseases. The need to prevent outbreaks of zoonosis drives demand for animal healthcare in the region.
Budget Constraints of Small Biotechnological Companies
One major restraint is the tight budget of small and mid-sized biotech companies, which form a significant customer base for CROs. As developing a new drug requires massive investments, biotech firms often have limited funds that restrict their outsourcing potential. Any uncertainty or delays in drug development can further strain their budgets, limiting new project approvals and restraining CRO revenue growth.